Imalia reports initial proof-of-concept data for the effect of IMA001,on the progression of markers of sickle cell disease (SCD) in the Townes HbSS experimental mouse model. IMA001administered at 185 mg/kg/day for up to 28 days, improves the critical hematological markers of SCD (e.g. hemoglobin level, hematocrit, Red blood cell (RBC) and reticulocyte counts…), reduces sickling and increases RBC half-life in the circulation. This feature on anemia alleviation has a direct physiological effect in the Townes mice, through mitigation in spleen size indicating a positive impact on stress erythropoiesis.